---
document_datetime: 2025-12-09 23:07:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/gilenya.html
document_name: gilenya.html
version: success
processing_time: 0.1681798
conversion_datetime: 2025-12-24 05:13:26.975821
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Gilenya

[RSS](/en/individual-human-medicine.xml/67136)

##### Authorised

This medicine is authorised for use in the European Union

fingolimod Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Gilenya](#news-on)
- [More information on Gilenya](#more-information-on-gilenya-1547)
- [More information on Gilenya](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Gilenya is a type of medicine known as a 'disease-modifying therapy' that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. 'Relapsing-remitting' means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.

Gilenya contains the active substance fingolimod.

Expand section

Collapse section

## How is Gilenya used?

Gilenya can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in multiple sclerosis. Gilenya is available as capsules (0.25 mg and 0.5 mg). The recommended dose for adults is one 0.5 mg capsule taken once a day by mouth, the recommended dose for children depends on body weight.

Because Gilenya decreases the heart rate and can affect the heart's electrical activity and rhythm, the patient's blood pressure and heart activity is checked before starting treatment and during treatment, and also if Gilenya treatment is restarted after an interruption. Details on the recommendations for monitoring patients are found in the summary of product characteristics.

For more information about using Gilenya, see the package leaflet or contact your doctor or pharmacist.

## How does Gilenya work?

In multiple sclerosis, the immune system (the body's defences) incorrectly attacks the protective sheath around the nerves in the brain and spinal cord. The active substance in Gilenya, fingolimod, prevents T cells (a type of white blood cell involved in the immune system) travelling from the lymph nodes towards the brain and spinal cord, thus limiting the damage they cause in multiple sclerosis. It does this by blocking the action of a receptor (target) on the T cells called the sphingosine-1- phosphate receptor, which is involved in controlling the movement of these cells in the body.

## What benefits of Gilenya have been shown in studies?

Three main studies in adults and one main study in children have found that Gilenya was more effective than placebo (a dummy treatment) or interferon beta-1a (another medicine for treating multiple sclerosis) in patients with relapsing-remitting multiple sclerosis. The main measure of effectiveness in all the studies was based on the number of relapses the patients experienced each year.

In two studies involving a total of 2,355 patients, Gilenya was compared with placebo over two years. Patients treated with Gilenya had around half the number of relapses compared with patients given placebo.

In a third study involving 1,292 patients, Gilenya was compared with interferon beta-1a over one year. Patients receiving Gilenya had around half the number of relapses compared with patients given interferon beta-1a.

In a study involving 215 children, Gilenya was compared with interferon beta-1a for up to 2 years. Of patients given Gilenya, 14% (15 out of 107) experienced relapses compared with 54% (58 out of 107) of patients given interferon beta-1a.

## What are the risks associated with Gilenya?

The most common side effects with Gilenya (seen in more than 1 patient in 10) are flu, sinusitis (inflammation of the sinuses), headache, cough, diarrhoea, back pain and raised liver enzyme levels (a sign of liver problems). The most serious side effects are infections, macular oedema (swelling in the central part of the retina at the back of the eye) and atrioventricular block (a type of heart rhythm disorder) at the start of treatment. For the full list of side effects of Gilenya, see the package leaflet.

Gilenya must not be used in patients at risk of infections due to a weakened immune system, patients with a severe infection or a long-term active infection such as hepatitis, and patients with cancer or severe liver problems. Gilenya must also not be used in patients with certain diseases affecting the heart and blood vessels or in those who have had such diseases or problems with the blood supply to the brain. Women should not become pregnant while taking Gilenya and for two months after treatment has stopped. For the full list of restrictions, see the package leaflet.

## Why is Gilenya authorised in the EU?

The European Medicines Agency concluded that there is clear evidence of the benefit of Gilenya in relapsing-remitting multiple sclerosis in both adults and children and noted that it had the benefit of being taken by mouth while most other medicines for this disease are given by injection. However, because of possible side effects, the Agency concluded that Gilenya should only be used in patients  who have a real need for the medicine either because their disease has not improved with at least one other disease-modifying therapy or because it is severe and getting worse rapidly. In addition, the Agency concluded that all patients should have their heart activity closely monitored after the first dose. The Agency decided that Gilenya's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Gilenya?

The company that markets Gilenya will provide results from a study to assess the risk of side effects  on the heart and circulation. It must also ensure that all doctors who prescribe Gilenya receive an information pack containing important safety information, including a checklist of the risks with Gilenya and the situations where its use is not recommended. The checklist includes information on the tests and monitoring in patients before and during treatment with Gilenya. The pack will also include information on a registry to collect data on babies born to women treated with Gilenya, as well as a patient reminder card for patients or their carers with key safety information.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Gilenya have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Gilenya are continuously monitored. Side effects reported with Gilenya are carefully evaluated and any necessary action taken to protect patients.

## Other information about Gilenya

Gilenya received a marketing authorisation valid throughout the EU on 17 March 2011.

Gilenya : EPAR - Medicine overview

Reference Number: EMA/685570/2018

English (EN) (81.82 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 18/12/2018

[View](/en/documents/overview/gilenya-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-716)

български (BG) (116.55 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/bg/documents/overview/gilenya-epar-medicine-overview_bg.pdf)

español (ES) (79.34 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/es/documents/overview/gilenya-epar-medicine-overview_es.pdf)

čeština (CS) (105.23 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/cs/documents/overview/gilenya-epar-medicine-overview_cs.pdf)

dansk (DA) (77.95 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/da/documents/overview/gilenya-epar-medicine-overview_da.pdf)

Deutsch (DE) (80.18 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/de/documents/overview/gilenya-epar-medicine-overview_de.pdf)

eesti keel (ET) (78.17 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/et/documents/overview/gilenya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (114.83 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/el/documents/overview/gilenya-epar-medicine-overview_el.pdf)

français (FR) (80.17 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/fr/documents/overview/gilenya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (100.97 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/hr/documents/overview/gilenya-epar-medicine-overview_hr.pdf)

italiano (IT) (78.42 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/it/documents/overview/gilenya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (103.74 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/lv/documents/overview/gilenya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (110.87 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/lt/documents/overview/gilenya-epar-medicine-overview_lt.pdf)

magyar (HU) (100.69 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/hu/documents/overview/gilenya-epar-medicine-overview_hu.pdf)

Malti (MT) (106.18 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/mt/documents/overview/gilenya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (78.58 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/nl/documents/overview/gilenya-epar-medicine-overview_nl.pdf)

polski (PL) (104.43 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/pl/documents/overview/gilenya-epar-medicine-overview_pl.pdf)

português (PT) (79.44 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/pt/documents/overview/gilenya-epar-medicine-overview_pt.pdf)

română (RO) (102.78 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/ro/documents/overview/gilenya-epar-medicine-overview_ro.pdf)

slovenčina (SK) (104.51 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/sk/documents/overview/gilenya-epar-medicine-overview_sk.pdf)

slovenščina (SL) (97.57 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/sl/documents/overview/gilenya-epar-medicine-overview_sl.pdf)

Suomi (FI) (77.97 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/fi/documents/overview/gilenya-epar-medicine-overview_fi.pdf)

svenska (SV) (78.64 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2018

[View](/sv/documents/overview/gilenya-epar-medicine-overview_sv.pdf)

Gilenya : EPAR - Risk Management Plan

English (EN) (1.4 MB - PDF)

**First published:** 01/06/2023

**Last updated:** 23/09/2025

[View](/en/documents/rmp/gilenya-epar-risk-management-plan_en.pdf)

## Product information

Gilenya : EPAR - Product Information

English (EN) (414.47 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 18/12/2024

[View](/en/documents/product-information/gilenya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-11)

български (BG) (608.38 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/bg/documents/product-information/gilenya-epar-product-information_bg.pdf)

español (ES) (463.74 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/es/documents/product-information/gilenya-epar-product-information_es.pdf)

čeština (CS) (560.98 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/cs/documents/product-information/gilenya-epar-product-information_cs.pdf)

dansk (DA) (459.46 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/da/documents/product-information/gilenya-epar-product-information_da.pdf)

Deutsch (DE) (485.65 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/de/documents/product-information/gilenya-epar-product-information_de.pdf)

eesti keel (ET) (492.63 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/et/documents/product-information/gilenya-epar-product-information_et.pdf)

ελληνικά (EL) (606.75 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/el/documents/product-information/gilenya-epar-product-information_el.pdf)

français (FR) (567.24 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/fr/documents/product-information/gilenya-epar-product-information_fr.pdf)

hrvatski (HR) (547.39 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/hr/documents/product-information/gilenya-epar-product-information_hr.pdf)

íslenska (IS) (456.46 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/is/documents/product-information/gilenya-epar-product-information_is.pdf)

italiano (IT) (481.27 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/it/documents/product-information/gilenya-epar-product-information_it.pdf)

latviešu valoda (LV) (540.03 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/lv/documents/product-information/gilenya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (575.5 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/lt/documents/product-information/gilenya-epar-product-information_lt.pdf)

magyar (HU) (553.68 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/hu/documents/product-information/gilenya-epar-product-information_hu.pdf)

Malti (MT) (596.26 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/mt/documents/product-information/gilenya-epar-product-information_mt.pdf)

Nederlands (NL) (469.63 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/nl/documents/product-information/gilenya-epar-product-information_nl.pdf)

norsk (NO) (448.46 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/no/documents/product-information/gilenya-epar-product-information_no.pdf)

polski (PL) (593.52 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/pl/documents/product-information/gilenya-epar-product-information_pl.pdf)

português (PT) (447.88 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/pt/documents/product-information/gilenya-epar-product-information_pt.pdf)

română (RO) (596.93 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/ro/documents/product-information/gilenya-epar-product-information_ro.pdf)

slovenčina (SK) (554.75 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/sk/documents/product-information/gilenya-epar-product-information_sk.pdf)

slovenščina (SL) (552.48 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/sl/documents/product-information/gilenya-epar-product-information_sl.pdf)

Suomi (FI) (476.82 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/fi/documents/product-information/gilenya-epar-product-information_fi.pdf)

svenska (SV) (458.94 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

18/12/2024

[View](/sv/documents/product-information/gilenya-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000257758 04/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Gilenya : EPAR - All Authorised presentations

English (EN) (47.06 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 10/05/2023

[View](/en/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (59.1 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/bg/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.41 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/es/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.33 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/cs/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.37 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/da/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.17 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/de/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.46 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/et/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (56.36 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/el/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_el.pdf)

français (FR) (49.93 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/fr/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.73 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/hr/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.48 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/is/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.09 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/it/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.38 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/lv/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.32 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/lt/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.24 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/hu/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.02 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/mt/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.77 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/nl/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.45 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/no/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_no.pdf)

polski (PL) (52.39 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/pl/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_pl.pdf)

português (PT) (47.09 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/pt/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_pt.pdf)

română (RO) (51.34 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/ro/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.14 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/sk/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (49.45 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/sl/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.82 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/fi/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (47.43 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

10/05/2023

[View](/sv/documents/all-authorised-presentations/gilenya-epar-all-authorised-presentations_sv.pdf)

Gilenya : EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (211.72 KB - PDF)

**First published:** 30/03/2011

**Last updated:** 06/07/2012

[View](/en/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (23)](#file-language-dropdown-448)

български (BG) (231.47 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/bg/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (207.42 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/es/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (221.57 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/cs/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (210.48 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/da/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (216.69 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/de/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (206.11 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/et/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (219.99 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/el/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (217.73 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/fr/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

íslenska (IS) (213.53 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/is/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_is.pdf)

italiano (IT) (213.29 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/it/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (218.73 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/lv/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (237.34 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/lt/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (216.8 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/hu/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (243.71 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/mt/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (211.51 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/nl/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

norsk (NO) (207.94 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/no/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_no.pdf)

polski (PL) (223.06 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/pl/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (210.78 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/pt/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (216.96 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/ro/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (222 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/sk/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (216.65 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/sl/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (208.83 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/fi/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (206.06 KB - PDF)

**First published:**

30/03/2011

**Last updated:**

06/07/2012

[View](/sv/documents/conditions-member-states/gilenya-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Gilenya Active substance fingolimod hydrochloride International non-proprietary name (INN) or common name fingolimod Therapeutic area (MeSH) Multiple Sclerosis Anatomical therapeutic chemical (ATC) code L04AE01

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:

- Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1).

or

- Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

## Authorisation details

EMA product number EMEA/H/C/002202 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 20/01/2011 Marketing authorisation issued 17/03/2011 Revision 40

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Gilenya : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.76 KB - PDF)

**First published:** 23/09/2025

[View](/en/documents/procedural-steps-after/gilenya-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Gilenya : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (350.65 KB - PDF)

**First published:** 02/09/2011

**Last updated:** 23/09/2025

[View](/en/documents/procedural-steps-after/gilenya-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Gilenya-PAM-0000295236 : EPAR - Assessment report

Reference Number: EMADOC-1700519818-2443340

English (EN) (2.06 MB - PDF)

**First published:** 02/12/2025

[View](/en/documents/variation-report/gilenya-pam-0000295236-epar-assessment-report_en.pdf)

Gilenya-H-C-2202-P46-039 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/716292/2021

English (EN) (424.66 KB - PDF)

**First published:** 06/12/2021

[View](/en/documents/variation-report/gilenya-h-c-2202-p46-039-epar-assessment-report_en.pdf)

Gilenya-H-C-PSUSA-00001393-202002: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/601114/2020

English (EN) (161.24 KB - PDF)

**First published:** 18/12/2020

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-202002-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-PSUSA-00001393-201902 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/601061/2019

English (EN) (69.89 KB - PDF)

**First published:** 20/12/2019

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-201902-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-2202-X-0044-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/779102/2018

English (EN) (775.18 KB - PDF)

**First published:** 19/02/2019

[View](/en/documents/variation-report/gilenya-h-c-2202-x-0044-g-epar-assessment-report-variation_en.pdf)

Gilenya-H-C-PSUSA-00001393-201802 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (67.4 KB - PDF)

**First published:** 18/12/2018

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-201802-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Gilenya (X/44/G)

Adopted

Reference Number: EMA/CHMP/612718/2018

English (EN) (72.63 KB - PDF)

**First published:** 21/09/2018

**Last updated:** 21/09/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya-x44g_en.pdf)

Gilenya-H-C-PSUSA-00001393-201702 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

English (EN) (66.83 KB - PDF)

**First published:** 12/02/2018

**Last updated:** 12/02/2018

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-201702-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Gilenya-H-C-PSUSA-00001393-201602 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/879483/2016

English (EN) (49.47 KB - PDF)

**First published:** 21/12/2016

**Last updated:** 21/12/2016

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-201602-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-PSUSA-00001393-201502 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/699354/2015

English (EN) (68.08 KB - PDF)

**First published:** 07/03/2016

**Last updated:** 07/03/2016

[View](/en/documents/scientific-conclusion/gilenya-h-c-psusa-00001393-201502-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-2202-II-0034 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/549382/2015

English (EN) (4.39 MB - PDF)

**First published:** 17/12/2015

**Last updated:** 17/12/2015

[View](/en/documents/variation-report/gilenya-h-c-2202-ii-0034-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Gilenya

Adopted

Reference Number: EMA/CHMP/627232/2015

English (EN) (71.32 KB - PDF)

**First published:** 25/09/2015

**Last updated:** 25/09/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya_en.pdf-0)

Gilenya-H-C-PSUV-0027 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/405985/2014

English (EN) (74.38 KB - PDF)

**First published:** 11/07/2014

**Last updated:** 11/07/2014

[View](/en/documents/scientific-conclusion/gilenya-h-c-psuv-0027-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-2202-II-0021 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/195551/2014

English (EN) (1.52 MB - PDF)

**First published:** 27/06/2014

**Last updated:** 27/06/2014

[View](/en/documents/variation-report/gilenya-h-c-2202-ii-0021-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Gilenya

Adopted

Reference Number: EMA/243755/2014

English (EN) (69.91 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 25/04/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-gilenya_en.pdf)

Gilenya-H-C-2202-PSUV-0023 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/177651/2014

English (EN) (71.94 KB - PDF)

**First published:** 01/04/2014

**Last updated:** 01/04/2014

[View](/en/documents/scientific-conclusion/gilenya-h-c-2202-psuv-0023-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Gilenya-H-C-2202-A20-0008 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/357270/2012

English (EN) (423.12 KB - PDF)

**First published:** 06/07/2012

**Last updated:** 06/07/2012

[View](/en/documents/variation-report/gilenya-h-c-2202-a20-0008-epar-assessment-report-article-20_en.pdf)

## Initial marketing authorisation documents

Gilenya : EPAR - Public assessment report

Adopted

Reference Number: EMA/108602/2011

English (EN) (1.68 MB - PDF)

**First published:** 30/03/2011

**Last updated:** 30/03/2011

[View](/en/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Gilenya

Adopted

Reference Number: EMA/26661/2011

English (EN) (120.1 KB - PDF)

**First published:** 21/01/2011

**Last updated:** 21/01/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-gilenya_en.pdf)

#### News on Gilenya

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019) 26/07/2019

[Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy](/en/news/updated-restrictions-gilenya-multiple-sclerosis-medicine-not-be-used-pregnancy) 26/07/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018) 21/09/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

[New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya](/en/news/new-recommendations-minimise-risks-rare-brain-infection-pml-type-skin-cancer-gilenya) 18/12/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 December 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-december-2015) 18/12/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-september-2015) 25/09/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 April 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-april-2012) 20/04/2012

[European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya](/en/news/european-medicines-agency-gives-new-advice-better-manage-risk-adverse-effects-heart-gilenya) 20/04/2012

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 January 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-january-2012) 20/01/2012

[European Medicines Agency starts review of Gilenya (fingolimod)](/en/news/european-medicines-agency-starts-review-gilenya-fingolimod) 20/01/2012

#### More information on Gilenya

Gilenya: Product Information as approved by the CHMP on 25 July 2019, pending endorsement by the European Commission

Summary:

Product Information as approved by the CHMP on 25 July 2019, pending endorsement by the European Commission

English (EN) (344.47 KB - PDF)

**First published:** 26/07/2019

[View](/en/documents/other/gilenya-product-information-approved-chmp-25-july-2019-pending-endorsement-european-commission_en.pdf)

Gilenya : Product Information as approved by the CHMP on 17 December 2015, pending endorsement by the European Commission

English (EN) (327.38 KB - PDF)

**First published:** 18/12/2015

**Last updated:** 18/12/2015

[View](/en/documents/other/gilenya-product-information-approved-chmp-17-december-2015-pending-endorsement-european-commission_en.pdf)

Questions and answers on the review of Gilenya - Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004

Reference Number: EMA/254587/2012

English (EN) (70.75 KB - PDF)

**First published:** 20/04/2012

**Last updated:** 20/04/2012

[View](/en/documents/medicine-qa/questions-and-answers-review-gilenya-outcome-procedure-under-article-20-regulation-ec-no-7262004_en.pdf)

Gilenya: Product information as approved by the CHMP on 19 April 2012, pending endorsement by the European Commission

English (EN) (383.29 KB - PDF)

**First published:** 20/04/2012

**Last updated:** 20/04/2012

[View](/en/documents/other/gilenya-product-information-approved-chmp-19-april-2012-pending-endorsement-european-commission_en.pdf)

Questions and answers on the ongoing review of Gilenya (fingolimod)

Reference Number: EMA/43541/2012

English (EN) (162.49 KB - PDF)

**First published:** 20/01/2012

**Last updated:** 20/01/2012

[View](/en/documents/medicine-qa/questions-and-answers-ongoing-review-gilenya-fingolimod_en.pdf)

#### More information on Gilenya

- [EMEA-000087-PIP01-07-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000087-pip01-07-m05)
- [Gilenya - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/gilenya)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)